Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower net loss of $1.14 per share in 2Q25 compared to the original estimate of $1.22 per share, indicating improved financial performance. Additionally, the clinical trials for OKI-219 showcased a favorable safety profile, with reported adverse events limited to Grade 1 treatment-related issues and no interruptions or discontinuations, demonstrating the drug's promising tolerability. This combination of reduced financial losses and strong clinical trial results contributes to a positive outlook for the company's growth potential in the biopharmaceutical sector.

Bears say

OnKure Therapeutics Inc. is facing a projected full-year net loss of $4.56 per share for 2025, a slight improvement from an earlier estimate of $4.75 per share, yet still indicating a challenging financial outlook. The company encounters significant risks, including potential negative clinical results with its lead asset, OKI-219, as well as delays in advancing its pipeline candidates and obtaining necessary regulatory approvals. Furthermore, competitive pressures in the biopharmaceutical market and long-term dilution risks further exacerbate concerns regarding the company's financial stability and growth prospects.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.